The human ether-a-go-go-related gene (hERG) encodes a channel that conducts the rapidly activating delayed rectifier K+ current (I Kr), which is important for cardiac repolarization. Mutations in hERG reduce IKr and cause congenital long QT syndrome (LQTS). More frequently, common medications can reduce IKr and cause LQTS as a side effect. Protein trafficking abnormalities are responsible for most hERG mutation-related LQTS and are recently recognized as a mechanism for druginduced LQTS. Whereas hERG trafficking has been studied in recombinant expression systems, there has been no reported study on cardiac IKr trafficking at the protein level. In the present study, we identified that IKr is present in cultured neonatal rat ventricular myocytes and can be robustly recorded using Cs+ as the charge carrier. We further discovered that 4,4′-(isopropylidenedithio)-bis-(2,6-di-t-butylphenol) (probucol), a cholesterol-lowering drug that induces LQTS, disrupted IKr trafficking and prolonged the cardiac action potential duration. Probucol did not directly block IKr. Probucol also disrupted hERG trafficking and did not block hERG channels expressed in human embryonic kidney 293 cells. We conclude that probucol induces LQTS by disrupting ether-a-go-go-related gene trafficking, and that primary culture of neonatal rat cardiomyocytes represents a useful system for studying native IKr trafficking.
|Number of pages||10|
|Journal||Journal of Pharmacology and Experimental Therapeutics|
|Publication status||Published - 1 Jun 2007|
ASJC Scopus subject areas
- Molecular Medicine